A Transformational Year: ImaginAb expands Pipeline to include Radiopharmaceutical Therapies, enters Multiple Partnerships, and Drives Forward Development of Investigational CD8 ImmunoPET Agent

LOS ANGELES, Oct. 4, 2022 /PRNewswire/ — ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and next generation therapeutic radiopharmaceuticals (RPT), is pleased to provide the following business update. Summary: ImaginAb…